NCT04011657

Brief Summary

Background Prospective review and feedback (PRF) of antibiotic prescriptions is a labor-intensive core strategy of antimicrobial stewardship (AMS). The investigators hypothesized that a computerized decision support system (CDSS) providing recommendations for antibiotics, investigations and referrals would reduce the requirement for PRF without causing harm. Methods A parallel-group, 1:1 block-cluster randomized, cross-over study was conducted in 32 medical and surgical wards from March to August 2017. The intervention arm comprised voluntary use of CDSS at first prescription of piperacillin-tazobactam or a carbapenem, while the control arm was compulsory CDSS. PRF was continued for both arms. Primary outcome was 30-day mortality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,257

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2017

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2018

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

July 1, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 8, 2019

Completed
Last Updated

November 14, 2019

Status Verified

November 1, 2019

Enrollment Period

7 months

First QC Date

July 1, 2019

Last Update Submit

November 12, 2019

Conditions

Keywords

computerized decision supportprospective review and feedbackantimicrobial stewardship

Outcome Measures

Primary Outcomes (1)

  • 30-day mortality

    Death at 30 days

    Follow-up up to 30 days from the start date of the first episode of piperacillin-tazobactam or carbapenem use

Secondary Outcomes (9)

  • 7-day clinical response

    Follow-up up to 7 days from the date of the first episode of piperacillin-tazobactam or carbapenem use

  • 30-day re-infection

    Re-start of piperacilin-tazobactam or carbapenem 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use

  • 30-day readmission

    Readmissions 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use

  • length of stay

    It is assessed from the date of admission till the date of discharge or up to 6 months

  • 6-months incidence of multi-drug resistant organisms

    up to 6 months (Clinical cultures only)

  • +4 more secondary outcomes

Study Arms (2)

Voluntary CDSS

EXPERIMENTAL

Voluntary use of computerized decision support with prospective review and feedback

Other: Compulsory CDSS

Compulsory CDSS

NO INTERVENTION

Compulsory use of computerized decision support with prospective review and feedback

Interventions

Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems

Voluntary CDSS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who are started on the 1st episode of piperacillin-tazobactam or carbapenem during the study period.
  • Medical and surgical wards

You may not qualify if:

  • Intensive care unit (ICU), high dependency and step-down care wards

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tan Tock Seng Hospital

Singapore, 308433, Singapore

Location

Related Publications (8)

  • Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13.

    PMID: 27080992BACKGROUND
  • Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4.

    PMID: 28178770BACKGROUND
  • Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, Ang B, Lye D, Teng CB. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2015 Apr;70(4):1219-25. doi: 10.1093/jac/dku479. Epub 2014 Dec 3.

    PMID: 25473028BACKGROUND
  • Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, van der Linden PD, Natsch S, Hertogh CMPM, Wolfs TFW, Schouten JA, Kullberg BJ, Prins JM. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Jul;16(7):847-856. doi: 10.1016/S1473-3099(16)00065-7. Epub 2016 Mar 3.

    PMID: 26947617BACKGROUND
  • Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother. 2010 May;65(5):1062-9. doi: 10.1093/jac/dkq058. Epub 2010 Mar 9.

    PMID: 20215130BACKGROUND
  • Thursky K. Use of computerized decision support systems to improve antibiotic prescribing. Expert Rev Anti Infect Ther. 2006 Jun;4(3):491-507. doi: 10.1586/14787210.4.3.491.

    PMID: 16771625BACKGROUND
  • Leibovici L, Kariv G, Paul M. Long-term survival in patients included in a randomized controlled trial of TREAT, a decision support system for antibiotic treatment. J Antimicrob Chemother. 2013 Nov;68(11):2664-6. doi: 10.1093/jac/dkt222. Epub 2013 Jun 5.

    PMID: 23743088BACKGROUND
  • Chow AL, Lye DC, Arah OA. Mortality Benefits of Antibiotic Computerised Decision Support System: Modifying Effects of Age. Sci Rep. 2015 Nov 30;5:17346. doi: 10.1038/srep17346.

    PMID: 26617195BACKGROUND

MeSH Terms

Conditions

Bacterial Infections

Condition Hierarchy (Ancestors)

Bacterial Infections and MycosesInfections

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
A parallel-group, 1:1 block-cluster randomized, cross-over study
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2019

First Posted

July 8, 2019

Study Start

March 1, 2017

Primary Completion

September 30, 2017

Study Completion

February 28, 2018

Last Updated

November 14, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will share

Anonymized data can be made available only after project agreement is made

Locations